At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Aug 10, 2026 at 08:00 ET
Cogent Biosciences reported Q2 2026 net loss of $96.4 million (EPS $-0.60 vs consensus $-0.56, a 6.2% miss) as R&D and G&A expenses scaled for commercial readiness ahead of dual PDUFA dates for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30). Cash position of $792.3 million plus $73.6 million in post-quarter ATM proceeds provides runway into late 2028, but the quarter's results are secondary to the binary regulatory catalysts.
- Net loss widened to $96.4M in Q2 2026 from $73.5M in Q2 2025, driven by increased R&D ($70.8M vs $62.2M) and G&A ($31.8M vs $13.4M) as the company builds commercial infrastructure
- Cash, equivalents and marketable securities stood at $792.3M as of June 30, 2026; pro forma cash of $865.9M including $73.6M in ATM proceeds
- EPS of $-0.60 missed consensus estimate of $-0.56 by 6.2%, a modest miss for a pre-revenue biotech where EPS is driven by expense timing, not business deterioration
- NDA for bezuclastinib in GIST accepted with priority review, PDUFA date of November 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access